Semaglutide has become one of the most talked-about medications in Canada, and for good reason. Originally developed for type 2 diabetes, it is now also approved for chronic weight management and has shown some of the strongest weight-loss results ever recorded in a Phase 3 program.
Ozempic, Wegovy and Rybelsus all contain the same active ingredient: semaglutide. This guide covers the science, the trial evidence, who qualifies, what it costs in Canada in 2026, and what the newly approved generic versions mean for patients. Specific topics like cost, side effects and getting a prescription each have their own dedicated pages, linked throughout.
What Is Semaglutide and How It Works
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. In simpler terms, it mimics a natural hormone the gut produces after eating. This hormone tells the brain the body is full, slows how fast food leaves the stomach, and helps regulate blood sugar. [1]
Novo Nordisk developed semaglutide by modifying the natural GLP-1 hormone so it lasts much longer in the body. Natural GLP-1 breaks down within minutes; semaglutide has a half-life of roughly 7 days, which is why only one injection per week is needed. [1]
Health Canada first approved it in 2018 for type 2 diabetes (as Ozempic) and later for chronic weight management (as Wegovy). An oral tablet, Rybelsus, is also available for diabetes. [9]
The GLP-1 Mechanism, Organ by Organ
The body naturally produces GLP-1 in the L-cells of the small intestine when food is eaten. Here is what semaglutide does once it activates GLP-1 receptors throughout the body:
- Brain (hypothalamus): Semaglutide crosses the blood-brain barrier and acts on appetite centres, reducing hunger signals and increasing fullness. This is the primary driver of the weight-loss effect. Functional MRI studies show reduced activation in brain areas tied to food cravings.
- Stomach: Slows gastric emptying, so food stays in the stomach longer. This contributes to feeling satisfied with smaller meals and is most noticeable in the first few months of treatment.
- Pancreas: Stimulates insulin release in a glucose-dependent manner and suppresses glucagon. This dual action is what makes it effective for diabetes management.
- Liver: Growing evidence suggests GLP-1 receptor agonists reduce liver fat, a potential benefit for patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the current name for what was previously called non-alcoholic fatty liver disease (NAFLD).
The key difference between semaglutide and older GLP-1 drugs like liraglutide (Saxenda/Victoza) is potency. Semaglutide has stronger binding affinity to GLP-1 receptors and a longer duration of action, which translates to better clinical outcomes at lower relative doses.
Generic Semaglutide Is Now Approved in Canada
Novo Nordisk's data exclusivity for semaglutide expired on January 4, 2026 and the Canadian patent covering the molecule has lapsed. Health Canada has now approved two generic semaglutide products: Dr. Reddy's Laboratories on April 28, 2026 (the first approval, making Canada the first G7 country to clear a generic) and Apotex's Apo-Semaglutide Injection on May 1, 2026 (the first Canadian-made generic). Seven more generic submissions are still under Health Canada review.
Both approved generics are now on pharmacy shelves. Apotex's Apo-Semaglutide and Dr. Reddy's generic began shipping to Canadian pharmacies on May 20, 2026. Cash prices have landed well below telehealth, based on early Canadian consumer reports: Costco Pharmacy is cheapest at roughly $88 to $99 per month, Walmart and No Frills run about $95 to $110, and Shoppers, Rexall and London Drugs sit around $100 to $120, compared to $250 to $310 for brand Ozempic. The wholesale gap explains why: per the Globe and Mail, Apotex lists $78.14 for a four-week supply versus $240.48 for the brand. Telehealth providers Felix and Hims both charge $149 per month all-in. Once a third generic is approved, public-plan out-of-pocket costs are projected to fall further under Canada's generic pricing framework.
Full timeline, manufacturer details and what this means for coverage: Generic Semaglutide in Canada.
Clinical Trial Results: STEP, SUSTAIN and SELECT
The evidence behind semaglutide comes from three major trial programs: SUSTAIN (diabetes), STEP (weight management) and SELECT (cardiovascular outcomes). These are among the largest and most rigorous trials ever conducted for these indications.
SUSTAIN Trials (Type 2 Diabetes)
The SUSTAIN program included 10 clinical trials involving over 10,000 patients with type 2 diabetes. Key findings:
| Trial | Comparison | HbA1c Reduction | Weight Loss |
|---|---|---|---|
| SUSTAIN 1 | vs. placebo | 1.45% to 1.55% | 3.7 to 4.5 kg |
| SUSTAIN 2 | vs. sitagliptin | 1.3% to 1.6% | 4.3 to 6.1 kg |
| SUSTAIN 6 | cardiovascular outcomes | 0.7% (vs placebo 0.4%) | 2.9 to 4.3 kg |
| SUSTAIN 7 | vs. dulaglutide | 1.5% to 1.8% | 4.6 to 6.5 kg |
SUSTAIN 6 was particularly important: it showed a 26% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death). [7] This is why many Canadian clinicians now consider semaglutide a first-line treatment for patients with type 2 diabetes and elevated cardiovascular risk. [10]
STEP Trials (Weight Management)
The STEP program focused on semaglutide 2.4 mg (the Wegovy dose) for chronic weight management. Results were unprecedented:
| Trial | Population | Average Weight Loss | % Losing 10%+ |
|---|---|---|---|
| STEP 1 | Adults with obesity (no diabetes) | 14.9% of body weight | 69.1% |
| STEP 2 | Adults with obesity + type 2 diabetes | 9.6% of body weight | 45.6% |
| STEP 3 | With intensive behavioural therapy | 16.0% of body weight | 74.7% |
| STEP 4 | Continuation vs. withdrawal | Continued loss vs. regain | Confirmed maintenance benefit |
| STEP 5 | 2-year data | 15.2% at 104 weeks | Sustained over 2 years |
For context, the average STEP 1 participant lost about 15% of body weight over 68 weeks. For a 100 kg person, that is roughly 15 kg (33 lbs). Previous weight-loss medications typically achieved 5% to 8% loss. [2]
SELECT Trial (Cardiovascular Outcomes Without Diabetes)
SELECT, published in 2023, enrolled over 17,600 adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared to placebo. [8] This was the first time a weight-management medication demonstrated direct cardiovascular benefit independent of diabetes treatment.
Semaglutide Brand Names in Canada
All three brands contain semaglutide but differ in approved use, dose and delivery method:
- Ozempic (injectable, type 2 diabetes): Available in 0.25 mg, 0.5 mg, 1 mg and 2 mg doses. Approved specifically for type 2 diabetes, though doctors sometimes prescribe it off-label for weight management. It is currently the most-prescribed version in Canada.
- Wegovy (injectable, weight management): The same semaglutide molecule at a higher maximum dose of 2.4 mg. Approved for chronic weight management in adults with a BMI of 30+, or 27+ with at least one weight-related condition.
- Rybelsus (oral tablet, type 2 diabetes): The only oral GLP-1 receptor agonist available. Comes in 3 mg, 7 mg and 14 mg doses. Must be taken on an empty stomach with a small sip of water, with at least 30 minutes before eating or drinking anything else.
Who Should (and Shouldn't) Take Semaglutide
Who qualifies
- Type 2 diabetes (Ozempic/Rybelsus): Adults whose blood sugar is not adequately controlled by metformin alone, or who need additional glycemic support. Especially recommended for patients with established cardiovascular disease or high cardiovascular risk. [10]
- Chronic weight management (Wegovy): Adults with a BMI of 30+, or 27+ with at least one weight-related health condition such as high blood pressure, type 2 diabetes, dyslipidemia or obstructive sleep apnea. [9]
A prescriber will also consider overall health profile — kidney function, thyroid history and other medications. Semaglutide works best combined with a reduced-calorie diet and increased physical activity.
Contraindications and who should avoid it
- Personal or family history of medullary thyroid carcinoma (MTC): In animal studies semaglutide caused thyroid C-cell tumours in rodents. This has not been confirmed in humans but is listed as a contraindication as a precaution.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This genetic condition increases the risk of MTC, so semaglutide is contraindicated.
- Pregnancy and breastfeeding: Semaglutide should be stopped at least 2 months before a planned pregnancy due to its long half-life.
- Type 1 diabetes: Not approved for type 1 diabetes and should not be used as a substitute for insulin.
- Severe gastrointestinal disease: Patients with gastroparesis or inflammatory bowel disease may experience worsened symptoms, since semaglutide slows gastric emptying.
Side Effects at a Glance
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea and constipation. These tend to be worst during dose escalation and improve over time. Roughly 40% to 50% of patients experience some nausea in the first few weeks. [2] [3]
More serious but rare side effects include pancreatitis, gallbladder problems and potential thyroid concerns. A detailed breakdown of every known side effect, how common each is, and practical management tips: Ozempic Side Effects for Canadian Patients.
Cost at a Glance
Without insurance, out-of-pocket pricing in Canada runs roughly $250–$310 per month for Ozempic and $500+ per month for Wegovy. Rybelsus pricing depends on dose. Ozempic is easier to access through insurance because most provincial formularies and private plans cover it for type 2 diabetes. Wegovy coverage is far more limited — most Canadian plans do not yet cover weight-management medications.
Generic semaglutide (covered above) launched in Canada in May 2026 and is now the cheapest cash option at roughly $88 to $99 per month at Costco Pharmacy. Full pricing breakdown, savings programs and insurance navigation: Semaglutide Cost in Canada.
How to Get Started
Semaglutide in Canada requires a prescription from a licensed physician or nurse practitioner. It is not available over the counter. A prescriber will assess eligibility for either the diabetes or weight-management indication, run baseline bloodwork, and start the lowest dose with a gradual titration schedule.
Online providers (telehealth)
Several Canadian telehealth clinics can complete the assessment, prescription and pharmacy delivery in a single online workflow — usually within 1–3 business days. Monthly pricing runs roughly $250 for Ozempic to $500+ for Wegovy, before insurance.
Provider reviews: MyRocky (top pick), Felix, Maple, Hims Canada, Jill Health, DooU and Raven.
Top pick: MyRocky (operated by Rocky Health Inc.) is our highest-rated Canadian GLP-1 provider in 2026 (9.4/10). Per-pen pricing is roughly comparable across the major Canadian telehealth services - what MyRocky wins on is total value: the $99 one-time consult includes lab work and the first prescription, there are no recurring quarterly fees, free fast delivery is included, and it operates its own LegitScript-certified pharmacy in Mississauga. MyRocky also serves all 10 provinces (Felix and Hims do not operate in Quebec) and has been trusted by 350,000+ Canadians. Visit MyRocky or read our full MyRocky review.
| Provider | Monthly Cost (Ozempic) | Consultation Fee | Coverage | Learn More |
|---|---|---|---|---|
| MyRocky ⭐ Top Pick | $300–$310 | $99 once (lab work included) | All 10 provinces | Visit MyRocky |
| Felix Health | Brand $250–$310 / Generic $149+ | $99 setup + $40 quarterly | All provinces except QC | Visit Felix |
| Maple | $270–$320 | $69 per consult | All provinces | Visit Maple |
| Hims Canada | Generic semaglutide available — pricing on consult | Included | Select provinces | Visit Hims |
| Jill Health | Pricing on assessment | Included in program | Most provinces | Visit Jill |
| DooU | Pricing on assessment | Included in program | Most provinces | Visit DooU |
| Raven | Pricing on assessment | Included in program | Most provinces | Visit Raven |
In-person (family doctor or walk-in + local pharmacy)
Any family doctor, nurse practitioner or walk-in clinician in Canada can prescribe semaglutide — no specialist referral required. In-person routes are usually the lowest-cost path if the visit is covered by provincial health insurance, since there is no consultation fee to layer on top of the medication. The script can then be filled at any pharmacy (Costco tends to have the lowest dispensing fees).
Full step-by-step — online vs. in-person, what to bring to the appointment, eligibility questions, and how titration works: How to Get Semaglutide in Canada.
The Future of Semaglutide
- Oral semaglutide for weight loss: The OASIS trial program is testing higher-dose oral semaglutide (up to 50 mg) specifically for weight management. Early results show weight loss comparable to the injectable version.
- CagriSema: Novo Nordisk's next-generation combination pairing semaglutide with cagrilintide (an amylin analogue). Phase 3 trials have shown average weight loss exceeding 20%.
- New indications: Semaglutide is under study for NASH/MASH, heart failure with preserved ejection fraction, chronic kidney disease and Alzheimer’s disease.
- Generic competition: As covered above, two Canadian-approved generic manufacturers (Dr. Reddy's and Apotex) cleared Health Canada in late April and early May 2026, with seven more submissions still under review. Both generics began shipping to Canadian pharmacies on May 20, 2026.
FAQ
Is semaglutide the same as Ozempic?
Semaglutide is the active drug ingredient. Ozempic is one brand name for injectable semaglutide approved for type 2 diabetes. Wegovy contains the same drug at a higher dose for weight management, and Rybelsus is the oral tablet form.
How much weight can I expect to lose on semaglutide?
Clinical trials showed average weight loss of about 15% of body weight over 68 weeks with the 2.4 mg dose (Wegovy). Individual results vary depending on adherence, diet, physical activity and starting weight. [2]
Do I need to take semaglutide forever?
Current evidence suggests stopping leads to weight regain in most patients. STEP 4 showed participants who switched to placebo regained about two-thirds of their lost weight. Most clinicians consider it a long-term medication. [5]
Is semaglutide safe long-term?
The longest published trial data runs to 2 years (STEP 5) with sustained weight loss and an acceptable safety profile. SELECT ran over 3 years and confirmed cardiovascular safety. [6] [8]
Can my family doctor prescribe semaglutide?
Yes. Any licensed physician or nurse practitioner in Canada can prescribe semaglutide. A specialist referral is not required.
Is generic semaglutide available in Canada?
Health Canada has now approved two generic semaglutide products: Dr. Reddy's Laboratories on April 28, 2026 and Apotex's Apo-Semaglutide Injection on May 1, 2026. Both began shipping to Canadian pharmacies on May 20, 2026, with seven more submissions still under review. Generic semaglutide is now the cheapest cash option in Canada at roughly $88 to $99 per month at Costco Pharmacy, well below brand Ozempic at $250 to $310. Once a third generic is approved, public-plan pricing drops further under Canada's generic pricing framework.
Sources
- Ozempic (semaglutide) Canadian Product Monograph — Novo Nordisk Canada / Health Canada: Mechanism, half-life, approved indications and dosing.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — Wilding JPH et al., NEJM 2021: Landmark 68-week weight-loss trial (14.9% mean body-weight loss).
- Semaglutide 2.4 mg in adults with overweight/obesity and type 2 diabetes (STEP 2) — Davies M et al., The Lancet 2021: Weight loss and glycemic outcomes in patients with T2D.
- Semaglutide with Intensive Behavioral Therapy (STEP 3) — Wadden TA et al., JAMA 2021: Combined pharmacotherapy + behavioural therapy effect size.
- Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4) — Rubino D et al., JAMA 2021: Weight regain after discontinuation (~two-thirds).
- Two-year effects of semaglutide (STEP 5) — Garvey WT et al., Nature Medicine 2022: Long-term safety and sustained weight loss at 104 weeks.
- Semaglutide and Cardiovascular Outcomes in T2D (SUSTAIN 6) — Marso SP et al., NEJM 2016: 26% MACE reduction vs. placebo in patients with type 2 diabetes.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — Lincoff AM et al., NEJM 2023: 20% MACE reduction in adults with CVD and overweight/obesity.
- Health Canada Drug Product Database — Ozempic, Wegovy, Rybelsus: Product listings, approved indications and current exclusivity status.
- Diabetes Canada 2024 Clinical Practice Guidelines: Canadian first-line recommendations for GLP-1 use in T2D.